KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Short-term Investments (2020 - 2025)

Historic Short-term Investments for CRISPR Therapeutics AG (CRSP) over the last 6 years, with Q4 2025 value amounting to $1.6 billion.

  • CRISPR Therapeutics AG's Short-term Investments rose 141.38% to $1.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 billion, marking a year-over-year increase of 141.38%. This contributed to the annual value of $1.6 billion for FY2025, which is 141.38% up from last year.
  • CRISPR Therapeutics AG's Short-term Investments amounted to $1.6 billion in Q4 2025, which was up 141.38% from $1.6 billion recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Short-term Investments registered a high of $1.7 billion during Q3 2024, and its lowest value of $680.1 million during Q1 2021.
  • For the 5-year period, CRISPR Therapeutics AG's Short-term Investments averaged around $1.4 billion, with its median value being $1.5 billion (2024).
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Short-term Investments skyrocketed by 35161.24% in 2021, and later plummeted by 1866.11% in 2023.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Short-term Investments stood at $1.5 billion in 2021, then grew by 10.12% to $1.6 billion in 2022, then fell by 18.66% to $1.3 billion in 2023, then rose by 23.11% to $1.6 billion in 2024, then grew by 1.41% to $1.6 billion in 2025.
  • Its Short-term Investments stands at $1.6 billion for Q4 2025, versus $1.6 billion for Q3 2025 and $1.5 billion for Q2 2025.